Primary hormone treatment in postmenopausal women with breast cancer

被引：0

作者：

Escalante S.M. ^{[1
]}

Sanz V.P. ^{[1
]}

Lescure A.R. ^{[1
]}

Navarro I.B. ^{[1
]}

Mena A.C. ^{[1
]}

机构：

[1] Department of Medical Oncology, Hospital General Universitario de Elche, 03202 Elche, Alicante

来源：

Clinical and Translational Oncology | 2006年 / 8卷 / 5期

关键词：

Aromatase inhibitors; Hormone therapy; Neoadjuvant treatment; Postmenopausal women;

D O I：

10.1007/s12094-006-0185-7

中图分类号：

学科分类号：

摘要：

Clinical benefits of hormone therapy in patients with hormone-sensitive tumors have been clearly established. Postmenopausal women with positive hormone receptors represent the largest group of patients in whom early stage breast cancer is diagnosed. Third-generation aromatase inhibitors (letrozole, anastrozole, and exemestane) are active and well tolerated in postmenopausal women with hormone-sensitive metastasic or locally advanced breast cancer as first or second line treatment. These are also valuable agents in the neoadjuvant setting in postmenopausal women, and even as single treatment in localized breast tumors in women not amenable to surgery. © FESEO 2006.

引用

页码：372 / 374

页数：2

共 50 条

[41] Risks of nonadherence to hormone therapy in Asian women with breast cancer
Hsieh, Kun-Pin
Chen, Li-Chia
Cheung, Kwok-Leung
Yang, Yi-Hsin
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2015, 31 (06) : 328 - 334
[42] Managing the risk of breast cancer in postmenopausal women: introduction
Vogel, Victor G.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2008, 15 (04): : 779 - 781
[43] Concurrent versus sequential hormonal and radiotherapy in postmenopausal women with early breast cancer
Abdeltawab, Asmaa Abdeltawab Abdellah
Ali, Samia A. K.
Mostafa, Hanan G. E.
Hassan, Mohamed A. E.
INDIAN JOURNAL OF CANCER, 2024, 61 (03) : 550 - 557
[44] Neoadjuvant endocrine treatment of women with breast cancer
Iturbe, Julian
Leone, Jose Pablo
Zwenger, Ariel
Vallejo, Carlos
Leone, Bernardo
ONCOLOGY REVIEWS, 2011, 5 (03) : 157 - 166
[45] Relationship between physical activity practice and metabolic profile of postmenopausal women under treatment with aromatase inhibitors for breast cancer
de Paulo, Thais R. S.
Viezel, Juliana
Aro, Bruna L.
Seidinger, Sylvia C.
Trindade, Ana Carolina A. C.
Christofaro, Diego G. D.
Freitas Junior, Ismael F.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2017, 216 : 33 - 37
[46] Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients
Quiroga-Garcia, Vanesa
Cirauqui-Cirauqui, Beatriz
Buges-Sanchez, Cristina
Angel Luna-Tomas, Miguel
Maria Castella-Fernandez, Eva
Mariscal-Martinez, Antonio
Margeli-Vila, Mireia
BREAST CARE, 2015, 10 (03) : 179 - 183
[47] Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer
Mrozek, Ewa
Layman, Rachel
Ramaswamy, Bhuvaneswari
Schaaf, Larry
Li, Xiaobai
Ottman, Susan
Shapiro, Charles L.
CLINICAL BREAST CANCER, 2012, 12 (02) : 151 - 156
[48] The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer
Pennery, Emma
EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2008, 12 (03) : 233 - 243
[49] Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer
Khosrow-Khavar, F.
Yin, H.
Barkun, A.
Bouganim, N.
Azoulay, L.
ANNALS OF ONCOLOGY, 2018, 29 (03) : 744 - 748
[50] Postmenopausal women with hormone receptor-positive breast cancer: Balancing benefit and toxicity from aromatase inhibitors
Ingle, James N.
BREAST, 2013, 22 : S180 - S183

← 1 2 3 4 5 →